The research is undertaken to develop new approaches to analyse protein glycosylation which is expected to assist in the characterisation of recombinant protein drugs, and to study potential
Alfresco Enterprise claimed that it has been chosen for its high quality document and records management solution offered at a competitive cost and its capacity to handle all
Under the terms of the agreement, Gilead will acquire CGI for up to $120m, the majority as an upfront payment and the remaining based on clinical development progress,
Canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 (SGLT2) inhibitor, is a member of a new class of antihyperglycemic therapies under development to treat type 2 diabetes. Canagliflozin Phase
Octreolin is an oral form of octreotide acetate that uses the company’s proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly. Chiasma said that if
XmAb5574, which will be renamed MOR208, is a humanised anti-CD19 monoclonal antibody for the treatment of B-cell malignancies. The contract provides MorphoSys with an exclusive worldwide license to
Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, is a once-daily oral treatment in type 2 diabetes. Boehringer Ingelheim said that the results of the trial were presented at the
Sanofi-aventis said that separate injections are being used by people following a basal-bolus insulin of a basal insulin and a mealtime insulin. The regimen is designed to address
Brinavess is an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. Merck and Cardiome Pharma said that the
NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME). NicOx’s new preclinical study demonstrated that NCX
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.